Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · Real-Time Price · USD

1.140

-0.020 (-1.72%)

At close: Mar 31, 2025, 4:00 PM

1.165

+0.025 (2.21%)

After-hours: Mar 31, 2025, 6:17 PM EDT

Virax Biolabs Group Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 30, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020
Revenue	0.08	0.16	0.01	-	0.12	0.1
Revenue Growth (YoY)	7.03%	1727.11%	-	-	23.97%	-
Cost of Revenue	0.05	0.11	0.01	-	0.13	0.05
Gross Profit	0.03	0.05	-0	-	-0.01	0.05
Selling, General & Admin	4.63	4.59	3.55	1.3	0.51	0.61
Research & Development	1.68	1.56	2.18	0.43	0.12	0.09
Operating Expenses	6.31	6.16	5.73	1.73	0.64	0.7
Operating Income	-6.28	-6.11	-5.73	-1.73	-0.64	-0.65
Interest Expense	-0.04	-0.03	-0.02	-0.02	-0.03	-0.09
Other Non Operating Income (Expenses)	-0.01	-0.02	-0	-0	0	0
EBT Excluding Unusual Items	-6.33	-6.15	-5.75	-1.75	-0.67	-0.74
Asset Writedown	-0.39	-0.39	-	-	-	-
Legal Settlements	-0.21	-0.21	-	-	-	-
Other Unusual Items	0.21	0.01	0.29	-	-	-
Pretax Income	-6.72	-6.74	-5.46	-1.75	-0.67	-0.74
Earnings From Continuing Operations	-6.58	-6.74	-5.46	-1.75	-0.67	-0.74
Minority Interest in Earnings	0	0.01	0	0.04	0.02	0.03
Net Income	-6.58	-6.73	-5.46	-1.71	-0.65	-0.71
Net Income to Common	-6.58	-6.73	-5.46	-1.71	-0.65	-0.71
Shares Outstanding (Basic)	3	2	1	1	0	0
Shares Outstanding (Diluted)	3	2	1	1	0	0
Shares Change (YoY)	50.43%	88.75%	11.15%	297.67%	130.43%	-
EPS (Basic)	-2.46	-3.36	-5.13	-1.79	-2.71	-6.81
EPS (Diluted)	-2.47	-3.36	-5.13	-1.79	-2.71	-6.81
Free Cash Flow	-5.28	-7.2	-4.18	-0.81	-0.59	-0.74
Free Cash Flow Per Share	-1.98	-3.59	-3.93	-0.85	-2.45	-7.13
Gross Margin	39.59%	32.34%	-15.94%	-	-7.62%	45.81%
Operating Margin	-7397.95%	-3903.69%	-66963.68%	-	-520.54%	-652.05%
Profit Margin	-7753.22%	-4304.81%	-63748.32%	-	-525.75%	-711.32%
Free Cash Flow Margin	-6220.66%	-4602.71%	-48823.35%	-	-476.65%	-745.54%
EBITDA	-6.12	-6.05	-	-	-	-
D&A For EBITDA	0.16	0.05	-	-	-	-
EBIT	-6.28	-6.11	-5.73	-1.73	-0.64	-0.65
Revenue as Reported	-	-	-	-	0.12	0.1

Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q